Antibodies to watch in 2022 von Kaplon, Hélène, Chenoweth, Alicia, Crescioli, Silvia, Reichert, Janice M.

Volltext

Antibodies to watch in 2020 von Kaplon, Hélène, Muralidharan, Mrinalini, Schneider, Zita, Reichert, Janice M.

Volltext

Antibodies to watch in 2023 von Kaplon, Hélène, Crescioli, Silvia, Chenoweth, Alicia, Visweswaraiah, Jyothsna, Reichert, Janice M.

Volltext

Antibodies to watch in 2019 von Kaplon, Hélène, Reichert, Janice M.

Volltext

The therapeutic monoclonal antibody market von Ecker, Dawn M, Jones, Susan Dana, Levine, Howard L

Volltext

Antibodies to watch in 2021 von Kaplon, Hélène, Reichert, Janice M.

Volltext

The making of bispecific antibodies von Brinkmann, Ulrich, Kontermann, Roland E.

Volltext

Structure, heterogeneity and developability assessment of therapeutic antibodies von Xu, Yingda, Wang, Dongdong, Mason, Bruce, Rossomando, Tony, Li, Ning, Liu, Dingjiang, Cheung, Jason K, Xu, Wei, Raghava, Smita, Katiyar, Amit, Nowak, Christine, Xiang, Tao, Dong, Diane D., Sun, Joanne, Beck, Alain, Liu, Hongcheng

Volltext

Antibodies to watch in 2024 von Crescioli, Silvia, Kaplon, Hélène, Chenoweth, Alicia, Wang, Lin, Visweswaraiah, Jyothsna, Reichert, Janice M.

Volltext

Predicting Antibody Developability Profiles Through Early Stage Discovery Screening von Bailly, Marc, Mieczkowski, Carl, Juan, Veronica, Metwally, Essam, Tomazela, Daniela, Baker, Jeanne, Uchida, Makiko, Kofman, Ester, Raoufi, Fahimeh, Motlagh, Soha, Yu, Yao, Park, Jihea, Raghava, Smita, Welsh, John, Rauscher, Michael, Raghunathan, Gopalan, Hsieh, Mark, Chen, Yi-Ling, Nguyen, Hang Thu, Nguyen, Nhung, Cipriano, Dan, Fayadat-Dilman, Laurence

Volltext

The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity von Pereira, Natasha A., Chan, Kah Fai, Lin, Pao Chun, Song, Zhiwei

Volltext

Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates von Donaghy, Heather

Volltext

Antibodies to watch in 2018 von Kaplon, Hélène, Reichert, Janice M.

Volltext

Targeting cancer with antibody-drug conjugates: Promises and challenges von Dean, Alexis Q., Luo, Shen, Twomey, Julianne D., Zhang, Baolin

Volltext

Phage display-derived human antibodies in clinical development and therapy von Frenzel, André, Schirrmann, Thomas, Hust, Michael

Volltext

Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit von Wang, Jie, Fei, Keke, Jing, Hua, Wu, Zhihai, Wu, Weiwei, Zhou, Shuaixiang, Ni, Haiqing, Chen, Bingliang, Xiong, Yan, Liu, Yanpeng, Peng, Bo, Yu, Dechao, Jiang, Haiping, Liu, Junjian

Volltext

Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease von Benschop, Robert J, Chow, Chi-Kin, Tian, Yu, Nelson, James, Barmettler, Barbra, Atwell, Shane, Clawson, David, Chai, Qing, Jones, Bryan, Fitchett, Jon, Torgerson, Stacy, Ji, Yan, Bina, Holly, Hu, Ningjie, Ghanem, Mahmoud, Manetta, Joseph, Wroblewski, Victor J, Lu, Jirong, Allan, Barrett W

Volltext

Site-specific antibody drug conjugates for cancer therapy von Panowski, Siler, Bhakta, Sunil, Raab, Helga, Polakis, Paul, Junutula, Jagath R

Volltext

Antibodies to watch in 2017 von Reichert, Janice M.

Volltext

Forced degradation of recombinant monoclonal antibodies: A practical guide von Nowak, Christine, K. Cheung, Jason, M. Dellatore, Shara, Katiyar, Amit, Bhat, Ram, Sun, Joanne, Ponniah, Gomathinayagam, Neill, Alyssa, Mason, Bruce, Beck, Alain, Liu, Hongcheng

Volltext